08:00 , Mar 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD36 (GPIV); macrophage scavenger receptor 1 (MSR-1; SR-A; CD204)

Cardiovascular disease INDICATION: Atherosclerosis In vitro and mouse studies suggest sugar-based amphiphilic nanoparticles could help treat atherosclerosis. Macrophage recruitment and oxidized low-density lipoprotein (LDL) uptake via scavenger receptors such as CD36 and MSR-1 contributes to...
07:00 , Mar 20, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

At least $440 million in new support for public-private partnerships was allocated last month globally. Almost $230 million of that amount is earmarked for the NIH 's Accelerating Medicines Partnership 1 ( see "Selected public-private...
08:00 , Feb 24, 2014 |  BC Week In Review  |  Company News

Montreal Heart Institute cardiovascular, diagnostic, genomics news

The institute announced the launch of the ARTERIA project to develop treatments and diagnostics for cardiovascular disease. Specifically, the project aims to validate and implement diagnostic tests of statin-induced muscle toxicity, validate genetic markers and...
08:00 , Feb 13, 2014 |  BC Innovations  |  Cover Story

Curb your fatty acids

A University of California, San Francisco team has uncovered a pathway for regulating absorption of fatty acids that could yield new targets for treating obesity. MFGE8 , an integrin ligand, controls the uptake of fat...
08:00 , Dec 12, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS CD36 (GPIV) In vitro studies suggest anti-CD36 antibodies could help treat HIV. In HIV-infected macrophages, an anti-CD36 mAb or...
07:00 , Aug 1, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Atherosclerosis; Alzheimer's disease (AD); diabetes; inflammation CD36 (GPIV) In vitro and mouse studies suggest inhibiting CD36 could help suppress inflammation in...
08:00 , Feb 21, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) CD36 (GPIV) Mouse studies suggest antagonizing CD36 could help treat cerebral amyloid angiopathy. Symptoms of cerebral amyloid angiopathy...
08:00 , Nov 14, 2011 |  BC Week In Review  |  Clinical News

Arteria preclinical data

In mice and rats, oral AP-5258 significantly inhibited the transfer of postprandial triglycerides vs. an inactive control (p<0.01). Arteria plans to start a Phase I trial of the CD36 (GPIV) inhibitor next year. Arteria S.A....